Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company miRagen Therapeutics and the University of Glasgow have signed an exclusive license agreement for intellectual property they developed as part of an ongoing collaboration for microRNA-145 in pulmonary arterial hypertension (PAH).
Subscribe to our email newsletter
The licensing agreement provides miRagen with exclusive rights to an important discovery made in collaboration with the University of Glasgow and the University of Cambridge, enabling miRagen to advance miR-145 inhibition as a potential therapeutic approach for PAH.
PAH is a devastating, progressive disease repelled by abnormal cellular development and blockage of small blood vessels in the lung, which further raises pulmonary arterial pressure and, ultimately, fatal right-sided heart failure.
miRagen Therapeutics president and chief executive officer William Marshall said the results generated during the firm’s collaboration suggest that microRNA-145 controls the expression of a complex biological network that is important in the development of the devastating disease
"This agreement is one part of miRagen’s core strategy to leverage our comprehensive expertise in microRNA biology and combine optimal targets and chemistries for the development of groundbreaking therapeutics," Marshall added.